altera-medtronic-case-analysis.docx

1018-00009 · Client 1018 · Strategy

altera-medtronic-case-analysis.docx DOCUMENT M&A / Corporate

150 / 176 ← → ✕

MEMORANDUM

TO: Leonard Cross, Responsible Partner; Sylvia Hartwell, Billing Partner

FROM: Garrett Simmons, Lead Associate; Leila Nazari, Working Associate

DATE: September 15, 2022

RE: Case Law Analysis — Altera Corp. v. Commissioner and Harborview Corporation, Inc. v. Commissioner: Applicability to Penterra Pharmaceuticals Corp. IRS Transfer Pricing Examination Defense

MATTER: 1018-00009 (Penterra Pharmaceuticals Corp. — IRS Examination Defense, TY 2017–2020)

EXAM TEAM ID: LB&I-NE-TP-2022-00641

Right-click to update Table of Contents

I. Executive Summary

This memorandum analyzes the two most significant recent judicial decisions on transfer pricing methodology — Altera Corp. v. Commissioner (addressing the inclusion of stock-based compensation in cost-sharing arrangement cost pools) and Harborview Corporation, Inc. v. Commissioner (addressing the comparable uncontrolled transaction methodology for intangible property royalties) — and evaluates their applicability to the transfer pricing positions of Penterra Pharmaceuticals Corp. ("PPC") in its ongoing IRS examination.

On May 16, 2022, the IRS Large Business and International Division ("LB&I"), Northeast Transfer Pricing Practice, opened an examination of PPC's federal income tax returns for tax years 2017 through 2020. The examination focuses on the transfer pricing methodology governing the intercompany relationship between PPC and its Irish intellectual property-holding subsidiary, Penterra Biopharma International DAC ("PBI"), a designated activity company incorporated in Ireland. The IRS examination team has identified three principal areas of challenge:

(1) The cost-sharing arrangement ("CSA") cost-sharing ratios and the platform contribution transaction ("PCT") valuation governing the allocation of intangible development costs and the initial transfer of pre-existing intangible property rights between PPC and PBI;

(2) The legacy intellectual property royalty rate of 4.5% charged by PPC to PBI for the license of certain pre-2012 pharmaceutical compounds; and

(3) PBI's economic substance as the counterparty to the CSA and the licensee of legacy intangible property.

Both Altera and Harborview Corporation address core questions arising under Internal Revenue Code ("IRC") Section 482 and the Treasury Regulations promulgated thereunder, including Treasury Regulation Sections 1.482-4 (methods for determining taxable income in connection with transfers of intangible property) and 1.482-7 (cost-sharing arrangements). These regulatory provisions are directly at issue in PPC's examination, and both decisions provide important — though distinct — guidance for structuring PPC's defense strategy.

Our summary conclusion is as follows: Altera supports the validity of Treasury's CSA regulations and establishes important precedent on the scope of Treasury's rulemaking authority under Section 482, but its central holding on the inclusion of stock-based compensation in cost-sharing pools is factually distinguishable from PPC's primary exposure areas. Harborview Corporation provides considerably stronger and more directly applicable support for PPC's defense of the 4.5% legacy IP royalty rate, validates rigorous comparability analysis under the comparable uncontrolled transaction ("CUT") method, and cautions against the IRS's selective use of comparable transaction data. Together, these decisions reinforce the importance of contemporaneous transfer pricing documentation and expert economic analysis — areas where PPC, with support from Crestfield & Associates LLP ("Crestfield") and Whitmore Valuation Group LLC ("WVG"), is well-positioned.

II. Background: PPC's Transfer Pricing Structure and IRS Examination

This section provides an overview of PPC's transfer pricing arrangements with PBI and summarizes the IRS's proposed adjustments for each of the challenged areas. A thorough understanding of the factual predicate is essential to assessing how Altera and Harborview Corporation apply to PPC's examination defense.

A. The Cost-Sharing Arrangement

PPC and PBI entered into a qualified cost-sharing arrangement effective July 1, 2012. PBI was incorporated on March 15, 2012, as a designated activity company under the laws of Ireland, with its registered office and principal place of business in Dublin. The CSA was structured in accordance with Treasury Regulation Section 1.482-7 and was intended to govern the development and exploitation of PPC's pharmaceutical intellectual property portfolio outside the Americas territory.

Under the terms of the CSA, PBI acquired rights to develop, manufacture, and exploit PPC's pharmaceutical IP portfolio — including patents, trade secrets, know-how, clinical data, regulatory filings, and related intangibles — in territories outside the Americas. In consideration for these rights, PBI was obligated to make two categories of payments:

(a) A one-time platform contribution transaction ("PCT") payment of $312 million, representing the arm's-length value of PBI's share of the pre-existing intangible property contributed by PPC to the CSA as of the effective date; and

(b) Ongoing cost-sharing payments calculated as PBI's share of qualified R&D expenditures, based on PBI's reasonably anticipated benefits ("RAB") from the intangible property developed under the CSA, as a proportion of total anticipated benefits to all CSA participants.

For the tax years at issue, PBI's cost-sharing percentages and corresponding payments were as follows:

The gradual increase in PBI's cost-sharing percentage over the four-year period reflects the growth of PBI's non-Americas commercial operations and corresponding reasonably anticipated benefits, consistent with the CSA's RAB methodology documented by Crestfield.

The IRS examination team proposes increasing PBI's cost-sharing percentages by approximately 8 to 12 percentage points in each year, revising the allocations as follows: 2017 — 48.2%; 2018 — 50.6%; 2019 — 52.3%; and 2020 — 53.7%. The basis for this proposed increase appears to be a recalculation of PBI's reasonably anticipated benefits using alternative revenue projections and market growth assumptions that differ materially from those used in PPC's contemporaneous documentation. The aggregate additional CSA cost-sharing payments resulting from the IRS's proposed adjustments total approximately $235.01 million across the four years at issue.

B. The Legacy IP Royalty Arrangement

Separate from the CSA, PBI licenses certain pre-2012 legacy pharmaceutical compounds from PPC under a license agreement executed contemporaneously with the CSA. These legacy compounds — primarily late-lifecycle products in therapeutic areas including cardiovascular medicine, diabetes management, and respiratory disease — were not contributed to the CSA cost pool and instead remain the exclusive intellectual property of PPC, licensed to PBI for exploitation in territories outside the Americas.

The royalty rate for the legacy IP license was established at 4.5% of PBI's net sales of legacy products in the non-Americas territories. This rate was determined based on a benchmarking study conducted by Crestfield at the time of the CSA's formation, which identified comparable uncontrolled license agreements for pharmaceutical compounds at similar stages in their product lifecycles.

Net sales of legacy products in the non-Americas territories for the years at issue were as follows:

The declining trajectory of legacy product net sales reflects the anticipated erosion of revenue from these mature products as patent protections lapse and generic competition enters the market. This declining revenue profile is consistent with the characterization of these products as legacy compounds and is relevant to the comparability analysis under the CUT method.

The IRS proposes increasing the royalty rate from 4.5% to 11.0%, citing its own analysis of comparable uncontrolled transaction data. The IRS asserts that PPC's selected comparable license agreements do not adequately reflect the value of the licensed intangible property and that transactions more closely comparable to PPC's legacy IP license support a significantly higher rate. The proposed adjustment to the royalty rate results in additional royalty income to PPC of approximately $188.04 million across the four tax years at issue.

C. The PCT Valuation

As noted above, PBI made a lump-sum PCT payment of $312 million at the inception of the CSA, representing the arm's-length value of PBI's share of PPC's pre-existing intangible property as of July 1, 2012. The PCT was valued using an income method / Discounted cash flow ("DCF") analysis, as documented in PPC's contemporaneous transfer pricing documentation prepared by Crestfield.

The IRS has proposed revaluing the PCT at $852 million. The IRS's valuation uses an income method with a weighted average cost of capital ("WACC") of 7.2%, which PPC believes materially understates the appropriate discount rate applicable to pre-revenue and early-lifecycle pharmaceutical intangibles in PBI's markets. The IRS's lower discount rate results in a substantially higher present value of projected future cash flows, driving the significant valuation disparity.

In response, PPC has engaged Whitmore Valuation Group LLC under a Kovel arrangement (reference number 1018-00009-KV, executed June 20, 2022) to conduct an independent valuation of the PCT. WVG, under the direction of Dr. Helena Vasquez (Managing Director) and Dr. Rohan Chakrabarti (Senior Vice President — Transfer Pricing), values the PCT in a range of $278 million to $361 million using a WACC of 9.8%. WVG's analysis incorporates risk adjustments specific to the pharmaceutical industry, including regulatory approval risk, market access risk, and foreign exchange exposure, which WVG contends justify a higher discount rate than the IRS's 7.2%.

D. Total Proposed Adjustment

The IRS's total proposed adjustment across all three challenged areas is summarized as follows:

In addition to the net proposed adjustment, the IRS has indicated its intention to assert a penalty under IRC Section 6662(e) (substantial valuation misstatement) in an amount of approximately $15.98 million. PPC's penalty defense relies on the contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP under the supervision of Susan Lam, Transfer Pricing Partner, which was prepared in accordance with the penalty-protection standards set forth in Treasury Regulation Section 1.6662-6(d) for all four tax years at issue.

III. Altera Corp. v. Commissioner

A. Procedural History

Altera Corp. v. Commissioner has a complex procedural history spanning several years and multiple tribunals. The case was first decided by the United States Tax Court in Altera Corp. v. Commissioner, 145 T.C. 91 (2015), where the Tax Court, in a unanimous 15-0 reviewed opinion, invalidated Treasury Regulation Section 1.482-7(d)(2). That regulation, promulgated as part of the 2003 temporary regulations and finalized in the 2011 regulations governing cost-sharing arrangements, required that stock-based compensation ("SBC") be included in the pool of intangible development costs shared among participants in a qualified CSA.

The Commissioner appealed the Tax Court's decision to the United States Court of Appeals for the Ninth Circuit, which reversed the Tax Court in Altera Corp. v. Commissioner, 926 F.3d 1061 (9th Cir. 2019). The Ninth Circuit held that the regulation was a valid exercise of Treasury's rulemaking authority under Section 482 and that it was neither arbitrary nor capricious under the Administrative Procedure Act ("APA"). The original three-judge panel decision was issued in 2018 but was subsequently withdrawn and replaced following the death of one panel member, Judge Stephen Reinhardt. The revised panel opinion, issued on June 7, 2019, reached the same result.

Altera petitioned for rehearing en banc, which the Ninth Circuit denied on February 10, 2020. Altera then filed a petition for writ of certiorari to the United States Supreme Court, which the Court denied on June 22, 2020. Altera Corp. v. Commissioner, 141 S. Ct. 131 (2020). The denial of certiorari left the Ninth Circuit's decision as the final word on the validity of the SBC cost-sharing regulation, at least within the Ninth Circuit.

B. Factual Background

Altera Corporation was a publicly traded semiconductor company headquartered in San Jose, California, which designed programmable logic devices and related technology. Altera maintained a CSA with its wholly-owned subsidiary, Altera International Ltd., incorporated in the Cayman Islands. Under the CSA, Altera and its Cayman subsidiary shared the costs of developing intangible property in proportion to their reasonably anticipated benefits from the resulting technology.

The central factual issue in Altera was whether stock-based compensation — including the cost of employee stock options and restricted stock units granted to Altera's U.S.-based research and development employees — must be included in the pool of intangible development costs shared with the Cayman subsidiary under the CSA. Altera excluded SBC from the shared cost pool, consistent with its position that arm's-length parties negotiating a cost-sharing arrangement would not agree to share SBC costs because such costs are not "real" economic costs in the same sense as cash expenditures and because unrelated parties in comparable arrangements do not share SBC.

The IRS challenged Altera's exclusion, asserting that Treasury Regulation Section 1.482-7(d)(2) required that SBC costs be included in the cost pool. The amounts at issue were significant: stock-based compensation constituted a substantial portion of Altera's total R&D expenditure, and its inclusion in the shared cost pool would have materially increased the subsidiary's cost-sharing obligation to the U.S. parent.

C. Tax Court Holding

The Tax Court held that Treasury Regulation Section 1.482-7(d)(2) was invalid under the APA. In its reviewed opinion, the Tax Court applied the "reasoned decision-making" standard articulated in Motor Vehicle Manufacturers Ass'n of the United States v. State Farm Mutual Automobile Insurance Co., 463 U.S. 29 (1983), and found that Treasury had failed to provide adequate justification in the rulemaking record for the requirement that SBC be included in cost-sharing pools.

Specifically, the Tax Court found that during the notice-and-comment rulemaking process leading to the final regulations, multiple commenters had argued persuasively that arm's-length parties in comparable uncontrolled cost-sharing arrangements do not share SBC costs. The commenters cited empirical evidence and economic analysis suggesting that third-party joint venturers and research partners do not typically include the cost of equity-based compensation in their shared development budgets. The Tax Court concluded that Treasury failed to adequately respond to these comments and did not provide a reasoned explanation for why arm's-length parties would share SBC costs, despite the evidence in the record suggesting they would not.

The Tax Court's unanimity was notable — all fifteen participating judges joined the reviewed opinion, signaling the strength of the court's conviction on the APA issue. The decision was widely viewed as a significant rebuke of Treasury's rulemaking process and raised broader questions about the vulnerability of transfer pricing regulations to APA-based challenges.

D. Ninth Circuit Reversal

The Ninth Circuit reversed the Tax Court's decision, holding that Treasury Regulation Section 1.482-7(d)(2) was a valid regulation entitled to deference under Chevron, U.S.A., Inc. v. Natural Resources Defense Council, Inc., 467 U.S. 837 (1984).

The Ninth Circuit's analysis proceeded in two steps, consistent with the Chevron framework:

Step One — Statutory Ambiguity. The court found that IRC Section 482 is ambiguous as to whether stock-based compensation must be included in the cost pools of qualified cost-sharing arrangements. Section 482 grants the Secretary broad authority to "distribute, apportion, or allocate gross income, deductions, credits, or allowances" among commonly controlled entities to clearly reflect income. The statute does not specifically address CSAs or define the components of shared cost pools, leaving a gap for Treasury to fill through regulation.

Step Two — Reasonable Interpretation. The court found that Treasury's interpretation — that SBC should be included in the cost pool to achieve arm's-length results — was a reasonable construction of the statute. The Ninth Circuit reasoned that SBC represents a real economic cost of compensating the employees who perform the R&D activities that generate the intangible property shared under a CSA. Excluding SBC from the cost pool would systematically understate the true cost of intangible development and shift income to low-tax jurisdictions in a manner inconsistent with the arm's-length standard.

The Ninth Circuit further found that Treasury provided sufficient explanation during the rulemaking process to satisfy the APA's requirements. The court adopted a more deferential standard than the Tax Court in assessing the adequacy of Treasury's response to commenters, holding that Treasury was not required to address every comment point-by-point or to marshal affirmative empirical evidence of arm's-length SBC sharing. Rather, Treasury was required only to articulate a rational basis for its regulatory choice, which the Ninth Circuit found it had done.

A critical element of the Ninth Circuit's reasoning was its conclusion that the arm's-length standard under Section 482 does not require that every element of a CSA cost pool have a directly observable third-party analog in uncontrolled transactions. The court recognized that cost-sharing arrangements between commonly controlled entities are sui generis structures with no perfect uncontrolled comparables, and that Treasury may therefore use its regulatory authority to define what costs must be shared in order to achieve arm's-length results, even in the absence of direct market evidence.

The Supreme Court's denial of certiorari effectively ended the litigation and left the Ninth Circuit's decision as the governing authority within that circuit. The Tax Court's original opinion was vacated, and the regulation remains in force nationwide.

E. Key Holdings and Principles from Altera

The Altera decision, as ultimately resolved by the Ninth Circuit, establishes several principles relevant to transfer pricing enforcement and CSA administration:

1. Validity of CSA Regulations. The Ninth Circuit confirmed the broad authority of Treasury to promulgate transfer pricing regulations under IRC Section 482, including the authority to define the components of cost pools in qualified cost-sharing arrangements under Treasury Regulation Section 1.482-7. This holding reinforces the regulatory foundation upon which PPC's CSA is structured and validates the comprehensive framework set forth in the 2011 final cost-sharing regulations.

2. Chevron Deference to Treasury. Transfer pricing regulations promulgated under Section 482 receive Chevron deference from the courts. This means that challenges to such regulations based on the absence of arm's-length comparables or disagreements with Treasury's economic assumptions face a high burden. A regulation will be upheld so long as it represents a reasonable interpretation of an ambiguous statutory provision, and Treasury is not required to demonstrate that its chosen approach is the only reasonable one.

3. Arm's-Length Standard Flexibility. The arm's-length standard does not require a perfect analog in uncontrolled transactions for every regulatory requirement governing controlled-party transactions. Treasury may adopt reasonable proxies, assumptions, and methodological requirements to operationalize the arm's-length standard, particularly in contexts — such as cost-sharing arrangements — where closely comparable uncontrolled transactions are scarce or nonexistent.

4. APA Rulemaking Standards. Treasury must provide a reasoned basis for its regulatory choices in the notice-and-comment rulemaking process, but the Ninth Circuit set a relatively deferential standard for what constitutes adequate explanation. The court's holding suggests that Treasury need not respond to every comment or marshal affirmative empirical evidence for its position, so long as the final regulation reflects rational decision-making and is not arbitrary or capricious.

F. Applicability to PPC's Positions

1. CSA Cost Pool Composition

PPC's CSA includes qualified R&D costs ranging from $487.3 million to $598.4 million annually during the 2017–2020 period. Altera affirms that the composition of the cost pool under Treasury Regulation Section 1.482-7 is subject to regulatory definition and that Treasury has broad authority to prescribe which categories of costs must be included in a shared development pool.

PPC should confirm that its treatment of stock-based compensation in the CSA cost pool is consistent with the final Altera holding. Specifically, if SBC costs attributable to employees performing qualified R&D activities were excluded from the shared cost pool in PPC's CSA for the years at issue, PPC may have exposure on this point under the regulation upheld by the Ninth Circuit. This is a threshold compliance question that should be verified with Crestfield's contemporaneous documentation. Based on our preliminary review, PPC's CSA documentation indicates that SBC was included in the cost pool for the years at issue, consistent with the regulation, but this should be confirmed.

It is significant, however, that the IRS's current examination does not appear to focus on SBC inclusion as a discrete challenge. Rather, the IRS's proposed adjustments to the CSA relate to the cost-sharing ratios — that is, the allocation percentages applied to the total cost pool — rather than the composition of the cost pool itself. The IRS's position is that PBI's reasonably anticipated benefits are higher than PPC has calculated, warranting higher allocation percentages, not that specific cost categories were improperly excluded from the pool. To that extent, Altera's holding on SBC inclusion is not directly responsive to the IRS's challenge.

2. Regulatory Deference and PPC's Risk

Altera underscores that courts will defer to Treasury's interpretation of Section 482 cost-sharing rules, provided that interpretation is reasonable. This deference cuts both ways for PPC.

On one hand, it supports the regulatory framework PPC relied upon in structuring its CSA. PPC's cost-sharing arrangement was designed in accordance with Treasury Regulation Section 1.482-7, and its cost-sharing methodology — including the calculation of reasonably anticipated benefits and the derivation of cost-sharing percentages — is grounded in the regulatory framework. To the extent the IRS seeks to apply a methodology that departs from the regulatory framework, Altera's affirmation of that framework is helpful to PPC.

On the other hand, Altera's broad deference to Treasury also means that the IRS's interpretation of the regulatory requirements — including the calculation of "reasonably anticipated benefits" under Treasury Regulation Section 1.482-7(e) — will itself receive deference if it is reasonable. PPC cannot assume that its own interpretation of the RAB methodology is the only reasonable one, and it must be prepared to defend the specific inputs and assumptions underlying its calculation against an IRS interpretation that may differ.

PPC's defense on this point should emphasize that its cost-sharing percentages (38.2% to 42.7%) are themselves derived from the regulatory framework, are supported by Crestfield's contemporaneous documentation, and reflect a methodology that is consistent with the regulations as upheld in Altera. The IRS's proposed percentages (48.2% to 53.7%) represent a substantial departure from PPC's calculations and should be subjected to rigorous scrutiny under the same regulatory framework.

3. Limitations of Altera for PPC's Defense

Several limitations constrain the applicability of Altera to PPC's defense:

First, Altera is a Ninth Circuit decision. PPC is headquartered in Princeton Junction, New Jersey, and would litigate in either the U.S. Tax Court (which sits nationwide and applies its own precedents, subject to the Golsen rule requiring it to follow the appellate circuit to which an appeal would lie) or, on appeal, in the United States Court of Appeals for the Third Circuit. The Ninth Circuit's holding is persuasive authority in the Third Circuit but is not binding. The Tax Court's original opinion invalidating the regulation was vacated by the Ninth Circuit's reversal, and the Tax Court has not independently adopted the Ninth Circuit's reasoning in subsequent cases. Accordingly, the precedential weight of Altera outside the Ninth Circuit is persuasive but not controlling.

Second, the core issue in Altera — whether SBC must be included in a CSA cost pool — is factually distinct from PPC's primary exposure areas, which involve cost-sharing ratios and the legacy IP royalty rate. While Altera provides useful general principles regarding Treasury's regulatory authority and the application of the arm's-length standard in the CSA context, it does not directly address the methodological questions at the heart of PPC's examination.

Third, Altera's emphasis on Chevron deference to Treasury could be deployed by the IRS to support its own proposed adjustments if the IRS frames its position as consistent with a reasonable interpretation of the regulations. PPC must be prepared to argue not only that its own methodology is reasonable but also that the IRS's specific methodology is unreasonable or unsupported by the regulatory framework — a higher burden than simply demonstrating that PPC's methodology is permissible.

IV. Harborview Corporation, Inc. v. Commissioner

A. Procedural History

Harborview Corporation, Inc. v. Commissioner has an even more extended procedural history than Altera, spanning three separate decisions over a six-year period. The case was first decided by the United States Tax Court in Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2016-112 (June 9, 2016). The Commissioner appealed the Tax Court's decision to the United States Court of Appeals for the Eighth Circuit, which affirmed in part and remanded in part in Harborview Corporation, Inc. v. Commissioner, 900 F.3d 610 (8th Cir. 2018). On remand, the Tax Court issued a revised decision in Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2022-84 (August 18, 2022) — a decision issued less than one month before the date of this memorandum and therefore representing the most current judicial guidance on the relevant methodological questions.

The case involved a multi-billion-dollar transfer pricing dispute between Harborview Corporation, Inc. (the U.S. parent), one of the world's largest medical device companies, and its wholly-owned manufacturing subsidiary organized in Puerto Rico ("MPROC"). The dispute centered on the arm's-length royalty rate for licenses of intangible property related to implantable cardiac rhythm devices (pacemakers, defibrillators, and related technology) from Harborview Corporation's U.S. operations to MPROC, which manufactured the devices in Puerto Rico for distribution worldwide.

B. Factual Background

Harborview Corporation licensed valuable intangible property — including patents, trade secrets, manufacturing know-how, product designs, and regulatory approvals — to its Puerto Rico subsidiary under an intercompany license agreement. The royalty rate was set based on the comparable uncontrolled transaction ("CUT") method, which is one of the specified methods for evaluating intercompany transfers of intangible property under Treasury Regulation Section 1.482-4(c).

Harborview Corporation's primary CUT was a 1992 license agreement between Harborview Corporation and Halcyon Partners LLC ("Pacesetter"), a third-party company operating in the same industry. Under the Pacesetter license, Harborview Corporation had granted Pacesetter rights to certain cardiac rhythm device technology in exchange for a royalty based on a percentage of net sales. Harborview Corporation argued that the Pacesetter license, with appropriate comparability adjustments, provided a reliable arm's-length benchmark for the intercompany royalty rate charged to MPROC.

The IRS challenged the royalty rate and proposed dramatically higher rates using an alternative methodology — specifically, the comparable profits method ("CPM"), also sometimes referred to as the transactional net margin method ("TNMM") in the OECD framework. The IRS asserted that the Pacesetter license was not a reliable CUT because it involved different intangible property, different contractual terms, and materially different economic conditions than the tested intercompany transaction. The IRS also argued that even if the CUT method were appropriate in theory, the adjustments required to make the Pacesetter license comparable to the MPROC license were so extensive and speculative as to render the CUT method unreliable.

The magnitude of the dispute was enormous. The IRS's proposed adjustments across the examined tax years exceeded $1.4 billion, making Harborview Corporation one of the largest transfer pricing cases in U.S. history by dollar amount. The case attracted substantial attention from the transfer pricing practitioner community, multinational corporations, and tax policymakers, and its outcome has significant implications for the application of transfer pricing methods to intangible property licensing arrangements.

C. Tax Court's Initial Decision (2016)

In its initial decision, the Tax Court sided largely with Harborview Corporation, applying the CUT method and relying on the Pacesetter license agreement as the most reliable comparable uncontrolled transaction.

The Tax Court's analysis proceeded in several steps. First, the court applied the "best method rule" under Treasury Regulation Section 1.482-1(c), which requires the selection of the transfer pricing method that "provides the most reliable measure of an arm's length result" based on all the facts and circumstances. The best method rule considers the degree of comparability between the tested transaction and uncontrolled comparables, the quality and completeness of the underlying data, the reliability of the assumptions required, and the sensitivity of the results to deficiencies in any of these factors.

After extensive analysis of the competing methodologies, the Tax Court found that the CUT method, applied using the Pacesetter license as the comparable transaction, was the best method for determining the arm's-length royalty. The court acknowledged that the Pacesetter license was not a perfect comparable — it involved somewhat different technology, covered a narrower range of products, and was executed under different market conditions — but found that these differences were susceptible to reasonably reliable adjustments.

The Tax Court made detailed adjustments to the Pacesetter-derived royalty rate to account for differences in the intangible property licensed, the functions performed by the parties, the risks assumed, and the economic conditions prevailing at the time of each respective agreement. After applying these comparability adjustments, the Tax Court arrived at a royalty rate that was significantly below the IRS's proposed rate but somewhat above the rate Harborview Corporation had originally applied.

The Tax Court also rejected the IRS's CPM-based alternative analysis. The court found that the IRS's CPM approach was less reliable than the adjusted CUT for several reasons: the comparable companies used by the IRS in its CPM benchmarking study were not sufficiently comparable to MPROC in terms of functions, assets, and risks; the IRS's CPM analysis failed to adequately account for the unique value of Harborview Corporation's intangible property; and the existence of a directly comparable uncontrolled transaction (the Pacesetter license) made reliance on indirect profit-based methods unnecessary and less reliable.

D. Eighth Circuit Decision (2018)

The Eighth Circuit affirmed the Tax Court's selection of the CUT method over the IRS's CPM approach, providing important appellate validation of the Tax Court's methodological determination. However, the Eighth Circuit remanded the case to the Tax Court for reconsideration of certain aspects of the comparability adjustments applied to the Pacesetter royalty rate, finding that the Tax Court had not adequately explained the basis for its specific adjustments.

The Eighth Circuit's key holdings can be summarized as follows:

First, the CUT method can be the best method under Treasury Regulation Section 1.482-1(c) even where the comparable transaction is not perfectly comparable to the tested transaction, provided that the differences between the comparable and the tested transaction can be identified and addressed through appropriate adjustments. The court emphasized that perfect comparability is an unattainable standard and that the best method rule requires selection of the most reliable method, not a perfect one.

Second, the best method rule requires consideration of the reliability of the method selected, the quality of the data underlying the analysis, and the reasonableness of the assumptions employed. These factors must be weighed against the alternatives — a method is not disqualified merely because it requires adjustments, but only if those adjustments are so numerous, substantial, or speculative as to render the method less reliable than an alternative.

Third, and critically for PPC's defense, the Eighth Circuit held that the IRS bears a significant burden of proof when challenging a taxpayer's chosen transfer pricing method, particularly when the taxpayer has contemporaneous documentation supporting that method. The court recognized that taxpayers who prepare and maintain contemporaneous transfer pricing documentation under Treasury Regulation Section 1.6662-6(d) are entitled to a presumption that their chosen methodology was reasonable, and the IRS must demonstrate that its proposed alternative produces a more reliable arm's-length result.

The Eighth Circuit's remand was narrowly focused: it did not question the Tax Court's selection of the CUT method or its rejection of the IRS's CPM approach, but rather required the Tax Court to provide a more detailed explanation of the specific numerical adjustments applied to the Pacesetter royalty rate. The Eighth Circuit found that some of the Tax Court's adjustments lacked adequate explanation in the record and directed the Tax Court to make clearer factual findings regarding the basis for its comparability corrections.

E. Tax Court on Remand (2022)

On remand, the Tax Court issued Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2022-84, on August 18, 2022. This decision, issued less than one month before the date of this memorandum, represents the most current judicial guidance on the application of the CUT method to intangible property royalties and is therefore of immediate relevance to PPC's examination defense.

On remand, the Tax Court reaffirmed its selection of the CUT method as the best method for determining the arm's-length royalty rate for the MPROC license. The court conducted a more detailed and thorough analysis of functional comparability, intangible property characteristics, and economic conditions affecting the Pacesetter license as compared to the tested transaction. The Tax Court applied revised comparability adjustments that were more fully explained and documented than those in its original decision, resulting in a modified royalty rate that differed somewhat from the rate determined in the original 2016 opinion.

The Tax Court again rejected the IRS's CPM-based approach, finding it less reliable than the adjusted CUT. The court noted that the IRS's profit-based analysis suffered from the same deficiencies identified in the original decision — including insufficient comparability of the benchmark companies and failure to adequately account for the unique value of Harborview Corporation's intangible property — and that these deficiencies had not been cured on remand.

The Tax Court's remand decision is significant for several reasons relevant to PPC. First, it demonstrates the Tax Court's sustained commitment to the CUT method as the best method when a comparable uncontrolled transaction is available, even when that transaction requires substantial adjustments. Second, it provides a detailed template for the type of comparability analysis that will satisfy the Eighth Circuit's requirements for adequate explanation — a template that PPC and WVG should follow in structuring their own CUT analysis. Third, it reaffirms the Tax Court's skepticism toward the IRS's reliance on profit-based methods as substitutes for CUTs in intangible property licensing disputes.

F. Key Holdings and Principles from Harborview Corporation

The Harborview Corporation litigation, taken as a whole across its three decisions, establishes several principles of direct relevance to PPC's examination defense:

1. Best Method Rule (Treas. Reg. § 1.482-1(c)). The CUT method can be the best method for determining arm's-length royalty rates for intangible property, even when the comparable transaction requires significant adjustments, if those adjustments are reasonably quantifiable and the underlying transaction is sufficiently comparable in economic substance. The selection of the best method is a facts-and-circumstances determination, and the CUT method is not disqualified merely because the comparable transaction is imperfect.

2. Comparability Standard for CUTs. Perfect comparability between the tested transaction and the uncontrolled comparable is not required. The relevant inquiry is whether the material differences between the two transactions can be reliably identified and adjusted for, taking into account the following factors:

(a) The nature and economic significance of the intangible property transferred or licensed in each transaction;

(b) The contractual terms of each transaction, including duration, exclusivity, geographic scope, and sublicensing rights;

(d) The functions performed, assets employed, and risks assumed by each party to the respective transactions.

3. Burden on the IRS. When a taxpayer relies on the CUT method and has contemporaneous transfer pricing documentation supporting its methodology, the IRS bears a heavy burden to demonstrate that its alternative methodology produces a more reliable arm's-length result. The IRS cannot simply assert that the taxpayer's CUT is imperfect; it must affirmatively demonstrate that its own methodology is more reliable under the best method rule.

4. Rejection of IRS's Reliance on CPM Where CUTs Exist. Both the Tax Court and the Eighth Circuit found that the IRS's CPM/profit-split analysis was less reliable when a directly comparable uncontrolled transaction existed, even an imperfect one. Profit-based methods are generally considered less reliable than transactional methods for intangible property transfers because they do not directly measure the arm's-length price or royalty for the specific intangible at issue.

5. Importance of Expert Economic Analysis. Both the Tax Court and the Eighth Circuit relied heavily on expert testimony regarding comparability adjustments, discount rates, revenue projections, and other elements of the economic analysis. The quality, rigor, and credibility of expert witnesses — particularly transfer pricing economists — were significant factors in the court's assessment of each party's methodology.

G. Applicability to PPC's Positions

1. Defense of the 4.5% Legacy IP Royalty Rate

Harborview Corporation provides the strongest precedential support for PPC's defense of the 4.5% royalty rate on legacy pharmaceutical compounds licensed from PPC to PBI.

WVG's CUT analysis, led by Dr. Helena Vasquez (Managing Director) as lead economist, identified 14 comparable uncontrolled pharmaceutical license agreements involving the license of mature or late-lifecycle pharmaceutical compounds in therapeutic categories broadly comparable to PPC's legacy product portfolio. The 14 CUTs were selected through a systematic search process using recognized databases (including Calderon Data Systems's Pharmaprojects database, the RoyaltySource pharmaceutical licensing database, and SEC filings) and were screened for comparability using criteria consistent with Treasury Regulation Section 1.482-4(c)(2).

The 14 CUTs yielded an interquartile range ("IQR") of 3.1% to 6.8% and a median of 4.4%. PPC's 4.5% royalty rate falls squarely within this interquartile range and is virtually at the median — within ten basis points — of the comparable data set. Under the arm's-length range provisions of Treasury Regulation Section 1.482-1(e)(2), a tested result that falls within the interquartile range of comparable results is generally regarded as within the range of arm's-length results, and no adjustment is warranted.

The IRS proposes an 11.0% rate based on its own selected CUTs. Under the Harborview Corporation framework, the IRS must demonstrate that its CUT selections are more reliable than PPC's — that is, that the IRS's comparable transactions are more closely comparable to PPC's legacy compound license than the 14 transactions identified by WVG. PPC should challenge the IRS's CUT selection criteria on multiple comparability grounds, including the nature of the intellectual property (early-stage vs. late-lifecycle), the therapeutic area (specialty vs. primary care), the geographic scope of the license (global vs. regional), and the exclusivity and sublicensing terms.

Harborview Corporation teaches that the comparability analysis must be rigorous and granular: courts will examine each claimed comparable in detail and assess whether the material differences between the comparable and the tested transaction have been identified and reliably adjusted for. PPC should be prepared to demonstrate, on a transaction-by-transaction basis, that the 14 CUTs identified by WVG are more closely comparable to PPC's legacy compound licenses than the transactions relied upon by the IRS.

2. Best Method Rule Application

Harborview Corporation reinforces that under the best method rule of Treasury Regulation Section 1.482-1(c) and (d), the CUT method is generally the most reliable method for evaluating intangible property licensing arrangements when comparable uncontrolled transactions are available. PPC can argue that the CUT method is the best method for evaluating the 4.5% royalty rate for several reasons that, taken together, make PPC's CUT analysis even more robust than the analysis upheld in Harborview Corporation:

• Multiple CUTs are available. PPC's CUT analysis relies on 14 comparable license agreements, as compared to the single Pacesetter license relied upon in Harborview Corporation. The availability of multiple CUTs provides a broader and more statistically reliable data set, reduces the risk of outlier bias inherent in reliance on a single comparable, and enhances the overall reliability of the arm's-length range determination.

• The interquartile range strongly corroborates PPC's rate. The IQR of 3.1% to 6.8% is a relatively narrow band, suggesting that the comparable transactions reflect a consistent market practice for royalties on late-lifecycle pharmaceutical compounds. PPC's 4.5% rate falls within this range and is supported by the central tendency (median of 4.4%) of the data set.

• PPC's rate was established contemporaneously. The 4.5% royalty rate was established as of July 1, 2012, based on then-available market data and a benchmarking study conducted by Crestfield. The contemporaneous nature of the rate determination is significant under Harborview Corporation, which emphasizes that the IRS bears a heavier burden when challenging a rate that was established based on a reasoned, contemporaneous analysis rather than reverse-engineered after the fact.

3. IRS's CUT Methodology Challenge

If the IRS relies on CUTs showing royalty rates closer to 11.0%, PPC should scrutinize the comparability of those transactions using the analytical framework articulated in Harborview Corporation. Specifically, PPC should examine the following factors for each of the IRS's claimed comparables:

• Therapeutic category. Did the IRS's CUTs involve the same or similar therapeutic categories as PPC's legacy compounds (primarily oncology, immunology, and rare disease)? Royalty rates in the pharmaceutical industry vary significantly by therapeutic area, and CUTs from unrelated therapeutic categories may not be reliable comparables.

• Product lifecycle stage. Were the licensed compounds in the IRS's CUTs at a similar stage in their product lifecycle as PPC's legacy compounds? PPC's legacy products are mature, declining-revenue compounds approaching or past patent expiration. CUTs involving early-stage, high-growth compounds would be expected to command higher royalty rates and would not be comparable to PPC's licenses.

• Geographic territories. Were the geographic territories in the IRS's CUTs comparable to the territories covered by PPC's legacy IP license (non-Americas)? Licenses covering global territories or large single-market territories (such as the United States) may reflect different risk profiles and revenue potential than non-Americas regional licenses.

• Contractual terms. Were the contractual terms of the IRS's CUTs comparable to PPC's license? Key terms to examine include duration, exclusivity, sublicensing rights, termination provisions, and milestone or minimum royalty obligations. Differences in these terms can materially affect the appropriate royalty rate.

Harborview Corporation requires that material differences between the tested transaction and the comparable be addressed through reliable adjustments, not dismissed. If the IRS's CUTs involve materially different intangible property, geographic scope, or contractual terms, the IRS must demonstrate that it has made appropriate adjustments to account for those differences — and that those adjustments are more reliable than the comparability adjustments applied by WVG to its 14 CUTs.

4. CPM/TNMM as an Alternative

In addition to the CUT analysis, WVG conducted a corroborative analysis under the comparable profits method / transactional net margin method ("CPM/TNMM"), testing PBI's operating margins against 22 comparable distributors and IP-holding companies in the pharmaceutical sector. WVG's CPM/TNMM analysis confirmed that PBI's operating margins fall within the interquartile range of the comparables in all four years at issue (2017–2020), providing additional support for the arm's-length nature of the intercompany pricing.

Under Harborview Corporation, where CUTs are available, the CUT method should take precedence over profit-based methods such as CPM and TNMM. However, the availability of a corroborative CPM/TNMM analysis strengthens PPC's overall position by demonstrating that the arm's-length character of the intercompany arrangements is confirmed under multiple independent methodologies. This "belt and suspenders" approach is consistent with the best method rule's emphasis on considering all available evidence of an arm's-length result.

5. PCT Valuation and Income Method

While Harborview Corporation primarily addressed royalty rates for ongoing intangible property licenses rather than lump-sum PCT valuations, the principles articulated in the decision regarding discount rate selection and revenue projection methodology are directly relevant to PPC's PCT valuation defense.

WVG used a WACC of 9.8% for the PCT income-method / DCF analysis, yielding a valuation range of $278 million to $361 million. The IRS used a WACC of 7.2%, yielding a valuation of $852 million. The 260 basis point difference in discount rates accounts for the vast majority of the $491 million to $574 million disparity between the two valuations.

Harborview Corporation underscores that assumptions regarding discount rates, revenue projections, growth rates, and other inputs to DCF analyses must be supportable and internally consistent, and that courts will critically examine the reasonableness of both parties' inputs. PPC should be prepared to demonstrate that WVG's 9.8% WACC reflects the risk profile of pre-revenue and early-lifecycle pharmaceutical intangibles in PBI's markets, incorporating industry-specific risk premiums for regulatory approval risk, market access and pricing risk, foreign exchange risk, and country-specific risk factors in PBI's non-Americas territories.

Conversely, PPC should challenge the IRS's 7.2% WACC as unreasonably low for pharmaceutical intangibles at the stage of development reflected in the CSA. A 7.2% WACC is more consistent with the cost of capital for a diversified, large-cap pharmaceutical company than with the risk-adjusted return required for pre-revenue intangible assets in development. The IRS's failure to adequately risk-adjust the discount rate is the type of analytical deficiency that Harborview Corporation identifies as undermining the reliability of an economic analysis.

6. Role of Contemporaneous Documentation

Harborview Corporation reinforces the significance of contemporaneous transfer pricing documentation in establishing the reasonableness of a taxpayer's chosen methodology and the reliability of the underlying economic analysis. Both the Tax Court and the Eighth Circuit gave weight to the fact that Harborview Corporation had established its royalty rate based on a reasoned analysis conducted at the time of the transaction, rather than developing its position retroactively in response to the IRS examination.

PPC's contemporaneous transfer pricing documentation was prepared by Crestfield & Associates LLP under the supervision of Susan Lam, Transfer Pricing Partner, in accordance with the penalty-protection standards of IRC Section 6662(e)(3)(B) and Treasury Regulation Section 1.6662-6(d) for all four years at issue (2017–2020). This documentation establishes the CSA and royalty methodologies under Treasury Regulation Sections 1.482-4 and 1.482-7 and provides a detailed economic analysis supporting the cost-sharing ratios, the 4.5% royalty rate, and the PCT valuation.

The existence of this contemporaneous documentation creates a strong factual foundation for PPC's defense under Harborview Corporation. It demonstrates that PPC's transfer pricing positions were not developed in hindsight but were established based on a rigorous, contemporaneous analysis conducted by qualified professionals. It also supports PPC's reasonable-cause defense against the proposed Section 6662(e) penalty, as discussed further in Section VI.D below.

V. Comparative Analysis: Altera and Harborview Corporation Together

A. Common Themes

Despite their different factual contexts and procedural postures, Altera and Harborview Corporation share several common themes that bear on PPC's examination defense.

Both cases underscore the primacy of the arm's-length standard under IRC Section 482 and the regulatory framework promulgated thereunder. In both cases, the courts evaluated the disputed transfer pricing issues through the lens of the arm's-length standard, assessing whether the intercompany arrangements at issue reflected the pricing that would have been agreed upon by unrelated parties transacting at arm's length. This analytical framework is the cornerstone of PPC's defense and should be the organizing principle for all of PPC's submissions to the IRS examination team.

Both cases establish that the IRS bears a significant evidentiary burden when challenging a taxpayer's contemporaneously documented transfer pricing methodology. In Altera, the IRS prevailed because the regulation it sought to enforce had been promulgated through the formal rulemaking process and was entitled to Chevron deference; but even there, the court evaluated whether Treasury had provided an adequate explanation for its regulatory choice. In Harborview Corporation, the IRS failed to meet its burden of demonstrating that its CPM-based alternative methodology was more reliable than the taxpayer's CUT-based approach, particularly where the taxpayer had contemporaneous documentation supporting its chosen method. Together, these cases establish that the IRS cannot simply disagree with a taxpayer's methodology; it must affirmatively demonstrate that its proposed alternative is superior under the best method rule.

Both cases emphasize the importance of rigorous economic analysis and expert testimony. In Altera, the Tax Court's initial decision turned in part on the quality of the economic evidence in the rulemaking record regarding whether arm's-length parties would share SBC costs. In Harborview Corporation, the Tax Court and the Eighth Circuit both relied heavily on expert testimony from transfer pricing economists regarding comparability adjustments, discount rates, and the reliability of the competing methodologies. PPC should ensure that WVG's economic analyses are structured to withstand the level of judicial scrutiny applied in both decisions.

B. Distinguishing Features Relevant to PPC

The following table summarizes the key distinguishing features of Altera and Harborview Corporation and their respective applicability to PPC's positions:

As this comparison illustrates, Harborview Corporation is the more directly applicable precedent for PPC's two largest exposure areas — the legacy IP royalty rate and the PCT valuation — while Altera is more relevant to the CSA cost-pool composition and structural questions. The combination of the two cases provides a comprehensive analytical framework for PPC's defense strategy.

C. Jurisdictional Considerations

PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. If PPC were to petition the United States Tax Court following the issuance of a statutory notice of deficiency, the Tax Court's own precedents would govern the resolution of the case, subject to the Golsen rule. Under Golsen v. Commissioner, 54 T.C. 742 (1970), the Tax Court follows the law of the circuit to which an appeal would lie when that circuit has addressed the issue. An appeal from a Tax Court decision involving PPC would lie in the Third Circuit, based on PPC's principal place of business.

The Tax Court's Harborview Corporation decisions — both the original 2016 opinion and the 2022 remand opinion — are directly applicable as Tax Court precedent. Because the Tax Court itself decided Harborview Corporation, its holdings regarding the best method rule, the comparability standard for CUTs, and the burden on the IRS are binding on the Tax Court in subsequent cases, absent a contrary holding by the Third Circuit.

Altera's Ninth Circuit holding is persuasive but not binding in the Third Circuit. However, it represents the current state of the law on the requirement that SBC be included in CSA cost pools, given that the Tax Court's original opinion invalidating the regulation was vacated by the Ninth Circuit's reversal. The regulation upheld in Altera — Treasury Regulation Section 1.482-7(d)(2) — applies nationwide by its terms, and there is no circuit split on its validity at present. Accordingly, while the Third Circuit would not be bound by the Ninth Circuit's reasoning, the practical effect is that the SBC regulation is in force and enforceable until a court in another circuit reaches a contrary conclusion.

Neither the Third Circuit nor the Tax Court has addressed transfer pricing methodology questions on facts closely analogous to PPC's — specifically, the application of the CUT method to pharmaceutical intangible property royalties or the valuation of a PCT in a pharmaceutical CSA. This absence of directly controlling authority means that both Altera and Harborview Corporation serve as important persuasive authorities, and PPC should cite them prominently in any judicial proceeding while acknowledging the jurisdictional limitations.

Additionally, PPC should be aware that if the case were litigated in the Tax Court, the Eighth Circuit's 2018 opinion in Harborview Corporation — while not binding under Golsen in a Third Circuit appeal — would be given significant weight as the only appellate court to have addressed the application of the best method rule to intangible property royalty disputes in this depth. The Third Circuit, if called upon to address these issues for the first time, would likely look to the Eighth Circuit's analysis as persuasive guidance.

VI. Strategic Recommendations

Based on the analysis set forth above, we make the following strategic recommendations for incorporating the Altera and Harborview Corporation precedents into PPC's examination defense at each stage of the proceedings.

A. For the IDR Response Phase (Current)

PPC is currently in the Information Document Request ("IDR") response phase of the examination. The IRS examination team has issued multiple IDRs requesting transfer pricing documentation, economic analyses, and supporting data. We recommend the following actions during this phase:

Cite Harborview Corporation in narrative responses regarding the royalty rate methodology. Any narrative responses to IDRs regarding the basis for PPC's 4.5% legacy IP royalty rate should cite Harborview Corporation to establish that the CUT method, supported by 14 comparable pharmaceutical license agreements with an interquartile range of 3.1% to 6.8% and a median of 4.4%, is the best method under Treasury Regulation Section 1.482-1(c) and (d). PPC's narrative should emphasize that the CUT analysis is even more robust than the analysis upheld in Harborview Corporation, which relied on a single comparable transaction, and that PPC's rate falls squarely within the arm's-length range.

Confirm compliance with Altera regarding SBC treatment. In responding to IDRs regarding the CSA cost pool composition, PPC should confirm that its treatment of stock-based compensation is consistent with the Altera holding and Treasury Regulation Section 1.482-7(d)(2). To the extent the IRS examination team has not yet raised SBC as a specific issue, PPC should avoid volunteering information on this topic beyond what is required by the IDR, but should ensure that its CSA documentation reflects SBC inclusion in the cost pool in conformity with the regulation.

Coordinate with WVG on comparability analysis. PPC should coordinate with WVG — specifically, Dr. Helena Vasquez and Dr. Rohan Chakrabarti — to ensure that the economic analyses being prepared and produced in response to IDRs are structured to withstand the type of granular comparability scrutiny applied by the Tax Court in the Harborview Corporation remand decision. Each of the 14 CUTs should be accompanied by a detailed comparability analysis addressing the nature of the licensed intangible property, the contractual terms, the economic conditions, and the functions, assets, and risks of the parties.

B. For a Potential Protest and Appeals

If the IRS issues a Revenue Agent Report proposing

PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT This memorandum was prepared in anticipation of litigation and at the direction of counsel. It is protected from disclosure by the attorney-client privilege, the work product doctrine, and all other applicable privileges. Any unauthorized disclosure, copying, or distribution of this memorandum or its contents is strictly prohibited.
MEMORANDUM
TO: Leonard Cross, Responsible Partner; Sylvia Hartwell, Billing Partner
FROM: Garrett Simmons, Lead Associate; Leila Nazari, Working Associate
DATE: September 15, 2022
RE: Case Law Analysis — Altera Corp. v. Commissioner and Harborview Corporation, Inc. v. Commissioner: Applicability to Penterra Pharmaceuticals Corp. IRS Transfer Pricing Examination Defense
MATTER: 1018-00009 (Penterra Pharmaceuticals Corp. — IRS Examination Defense, TY 2017–2020)
EXAM TEAM ID: LB&I-NE-TP-2022-00641
Right-click to update Table of Contents
I. Executive Summary
This memorandum analyzes the two most significant recent judicial decisions on transfer pricing methodology — Altera Corp. v. Commissioner (addressing the inclusion of stock-based compensation in cost-sharing arrangement cost pools) and Harborview Corporation, Inc. v. Commissioner (addressing the comparable uncontrolled transaction methodology for intangible property royalties) — and evaluates their applicability to the transfer pricing positions of Penterra Pharmaceuticals Corp. ("PPC") in its ongoing IRS examination.
On May 16, 2022, the IRS Large Business and International Division ("LB&I"), Northeast Transfer Pricing Practice, opened an examination of PPC's federal income tax returns for tax years 2017 through 2020. The examination focuses on the transfer pricing methodology governing the intercompany relationship between PPC and its Irish intellectual property-holding subsidiary, Penterra Biopharma International DAC ("PBI"), a designated activity company incorporated in Ireland. The IRS examination team has identified three principal areas of challenge:
(1) The cost-sharing arrangement ("CSA") cost-sharing ratios and the platform contribution transaction ("PCT") valuation governing the allocation of intangible development costs and the initial transfer of pre-existing intangible property rights between PPC and PBI;
(2) The legacy intellectual property royalty rate of 4.5% charged by PPC to PBI for the license of certain pre-2012 pharmaceutical compounds; and
(3) PBI's economic substance as the counterparty to the CSA and the licensee of legacy intangible property.
Both Altera and Harborview Corporation address core questions arising under Internal Revenue Code ("IRC") Section 482 and the Treasury Regulations promulgated thereunder, including Treasury Regulation Sections 1.482-4 (methods for determining taxable income in connection with transfers of intangible property) and 1.482-7 (cost-sharing arrangements). These regulatory provisions are directly at issue in PPC's examination, and both decisions provide important — though distinct — guidance for structuring PPC's defense strategy.
Our summary conclusion is as follows: Altera supports the validity of Treasury's CSA regulations and establishes important precedent on the scope of Treasury's rulemaking authority under Section 482, but its central holding on the inclusion of stock-based compensation in cost-sharing pools is factually distinguishable from PPC's primary exposure areas. Harborview Corporation provides considerably stronger and more directly applicable support for PPC's defense of the 4.5% legacy IP royalty rate, validates rigorous comparability analysis under the comparable uncontrolled transaction ("CUT") method, and cautions against the IRS's selective use of comparable transaction data. Together, these decisions reinforce the importance of contemporaneous transfer pricing documentation and expert economic analysis — areas where PPC, with support from Crestfield & Associates LLP ("Crestfield") and Whitmore Valuation Group LLC ("WVG"), is well-positioned.
II. Background: PPC's Transfer Pricing Structure and IRS Examination
This section provides an overview of PPC's transfer pricing arrangements with PBI and summarizes the IRS's proposed adjustments for each of the challenged areas. A thorough understanding of the factual predicate is essential to assessing how Altera and Harborview Corporation apply to PPC's examination defense.
A. The Cost-Sharing Arrangement
PPC and PBI entered into a qualified cost-sharing arrangement effective July 1, 2012. PBI was incorporated on March 15, 2012, as a designated activity company under the laws of Ireland, with its registered office and principal place of business in Dublin. The CSA was structured in accordance with Treasury Regulation Section 1.482-7 and was intended to govern the development and exploitation of PPC's pharmaceutical intellectual property portfolio outside the Americas territory.
Under the terms of the CSA, PBI acquired rights to develop, manufacture, and exploit PPC's pharmaceutical IP portfolio — including patents, trade secrets, know-how, clinical data, regulatory filings, and related intangibles — in territories outside the Americas. In consideration for these rights, PBI was obligated to make two categories of payments:
(a) A one-time platform contribution transaction ("PCT") payment of $312 million, representing the arm's-length value of PBI's share of the pre-existing intangible property contributed by PPC to the CSA as of the effective date; and
(b) Ongoing cost-sharing payments calculated as PBI's share of qualified R&D expenditures, based on PBI's reasonably anticipated benefits ("RAB") from the intangible property developed under the CSA, as a proportion of total anticipated benefits to all CSA participants.
For the tax years at issue, PBI's cost-sharing percentages and corresponding payments were as follows:
The gradual increase in PBI's cost-sharing percentage over the four-year period reflects the growth of PBI's non-Americas commercial operations and corresponding reasonably anticipated benefits, consistent with the CSA's RAB methodology documented by Crestfield.
The IRS examination team proposes increasing PBI's cost-sharing percentages by approximately 8 to 12 percentage points in each year, revising the allocations as follows: 2017 — 48.2%; 2018 — 50.6%; 2019 — 52.3%; and 2020 — 53.7%. The basis for this proposed increase appears to be a recalculation of PBI's reasonably anticipated benefits using alternative revenue projections and market growth assumptions that differ materially from those used in PPC's contemporaneous documentation. The aggregate additional CSA cost-sharing payments resulting from the IRS's proposed adjustments total approximately $235.01 million across the four years at issue.
B. The Legacy IP Royalty Arrangement
Separate from the CSA, PBI licenses certain pre-2012 legacy pharmaceutical compounds from PPC under a license agreement executed contemporaneously with the CSA. These legacy compounds — primarily late-lifecycle products in therapeutic areas including cardiovascular medicine, diabetes management, and respiratory disease — were not contributed to the CSA cost pool and instead remain the exclusive intellectual property of PPC, licensed to PBI for exploitation in territories outside the Americas.
The royalty rate for the legacy IP license was established at 4.5% of PBI's net sales of legacy products in the non-Americas territories. This rate was determined based on a benchmarking study conducted by Crestfield at the time of the CSA's formation, which identified comparable uncontrolled license agreements for pharmaceutical compounds at similar stages in their product lifecycles.
Net sales of legacy products in the non-Americas territories for the years at issue were as follows:
The declining trajectory of legacy product net sales reflects the anticipated erosion of revenue from these mature products as patent protections lapse and generic competition enters the market. This declining revenue profile is consistent with the characterization of these products as legacy compounds and is relevant to the comparability analysis under the CUT method.
The IRS proposes increasing the royalty rate from 4.5% to 11.0%, citing its own analysis of comparable uncontrolled transaction data. The IRS asserts that PPC's selected comparable license agreements do not adequately reflect the value of the licensed intangible property and that transactions more closely comparable to PPC's legacy IP license support a significantly higher rate. The proposed adjustment to the royalty rate results in additional royalty income to PPC of approximately $188.04 million across the four tax years at issue.
C. The PCT Valuation
As noted above, PBI made a lump-sum PCT payment of $312 million at the inception of the CSA, representing the arm's-length value of PBI's share of PPC's pre-existing intangible property as of July 1, 2012. The PCT was valued using an income method / Discounted cash flow ("DCF") analysis, as documented in PPC's contemporaneous transfer pricing documentation prepared by Crestfield.
The IRS has proposed revaluing the PCT at $852 million. The IRS's valuation uses an income method with a weighted average cost of capital ("WACC") of 7.2%, which PPC believes materially understates the appropriate discount rate applicable to pre-revenue and early-lifecycle pharmaceutical intangibles in PBI's markets. The IRS's lower discount rate results in a substantially higher present value of projected future cash flows, driving the significant valuation disparity.
In response, PPC has engaged Whitmore Valuation Group LLC under a Kovel arrangement (reference number 1018-00009-KV, executed June 20, 2022) to conduct an independent valuation of the PCT. WVG, under the direction of Dr. Helena Vasquez (Managing Director) and Dr. Rohan Chakrabarti (Senior Vice President — Transfer Pricing), values the PCT in a range of $278 million to $361 million using a WACC of 9.8%. WVG's analysis incorporates risk adjustments specific to the pharmaceutical industry, including regulatory approval risk, market access risk, and foreign exchange exposure, which WVG contends justify a higher discount rate than the IRS's 7.2%.
D. Total Proposed Adjustment
The IRS's total proposed adjustment across all three challenged areas is summarized as follows:
In addition to the net proposed adjustment, the IRS has indicated its intention to assert a penalty under IRC Section 6662(e) (substantial valuation misstatement) in an amount of approximately $15.98 million. PPC's penalty defense relies on the contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP under the supervision of Susan Lam, Transfer Pricing Partner, which was prepared in accordance with the penalty-protection standards set forth in Treasury Regulation Section 1.6662-6(d) for all four tax years at issue.
III. Altera Corp. v. Commissioner
A. Procedural History
Altera Corp. v. Commissioner has a complex procedural history spanning several years and multiple tribunals. The case was first decided by the United States Tax Court in Altera Corp. v. Commissioner, 145 T.C. 91 (2015), where the Tax Court, in a unanimous 15-0 reviewed opinion, invalidated Treasury Regulation Section 1.482-7(d)(2). That regulation, promulgated as part of the 2003 temporary regulations and finalized in the 2011 regulations governing cost-sharing arrangements, required that stock-based compensation ("SBC") be included in the pool of intangible development costs shared among participants in a qualified CSA.
The Commissioner appealed the Tax Court's decision to the United States Court of Appeals for the Ninth Circuit, which reversed the Tax Court in Altera Corp. v. Commissioner, 926 F.3d 1061 (9th Cir. 2019). The Ninth Circuit held that the regulation was a valid exercise of Treasury's rulemaking authority under Section 482 and that it was neither arbitrary nor capricious under the Administrative Procedure Act ("APA"). The original three-judge panel decision was issued in 2018 but was subsequently withdrawn and replaced following the death of one panel member, Judge Stephen Reinhardt. The revised panel opinion, issued on June 7, 2019, reached the same result.
Altera petitioned for rehearing en banc, which the Ninth Circuit denied on February 10, 2020. Altera then filed a petition for writ of certiorari to the United States Supreme Court, which the Court denied on June 22, 2020. Altera Corp. v. Commissioner, 141 S. Ct. 131 (2020). The denial of certiorari left the Ninth Circuit's decision as the final word on the validity of the SBC cost-sharing regulation, at least within the Ninth Circuit.
B. Factual Background
Altera Corporation was a publicly traded semiconductor company headquartered in San Jose, California, which designed programmable logic devices and related technology. Altera maintained a CSA with its wholly-owned subsidiary, Altera International Ltd., incorporated in the Cayman Islands. Under the CSA, Altera and its Cayman subsidiary shared the costs of developing intangible property in proportion to their reasonably anticipated benefits from the resulting technology.
The central factual issue in Altera was whether stock-based compensation — including the cost of employee stock options and restricted stock units granted to Altera's U.S.-based research and development employees — must be included in the pool of intangible development costs shared with the Cayman subsidiary under the CSA. Altera excluded SBC from the shared cost pool, consistent with its position that arm's-length parties negotiating a cost-sharing arrangement would not agree to share SBC costs because such costs are not "real" economic costs in the same sense as cash expenditures and because unrelated parties in comparable arrangements do not share SBC.
The IRS challenged Altera's exclusion, asserting that Treasury Regulation Section 1.482-7(d)(2) required that SBC costs be included in the cost pool. The amounts at issue were significant: stock-based compensation constituted a substantial portion of Altera's total R&D expenditure, and its inclusion in the shared cost pool would have materially increased the subsidiary's cost-sharing obligation to the U.S. parent.
C. Tax Court Holding
The Tax Court held that Treasury Regulation Section 1.482-7(d)(2) was invalid under the APA. In its reviewed opinion, the Tax Court applied the "reasoned decision-making" standard articulated in Motor Vehicle Manufacturers Ass'n of the United States v. State Farm Mutual Automobile Insurance Co., 463 U.S. 29 (1983), and found that Treasury had failed to provide adequate justification in the rulemaking record for the requirement that SBC be included in cost-sharing pools.
Specifically, the Tax Court found that during the notice-and-comment rulemaking process leading to the final regulations, multiple commenters had argued persuasively that arm's-length parties in comparable uncontrolled cost-sharing arrangements do not share SBC costs. The commenters cited empirical evidence and economic analysis suggesting that third-party joint venturers and research partners do not typically include the cost of equity-based compensation in their shared development budgets. The Tax Court concluded that Treasury failed to adequately respond to these comments and did not provide a reasoned explanation for why arm's-length parties would share SBC costs, despite the evidence in the record suggesting they would not.
The Tax Court's unanimity was notable — all fifteen participating judges joined the reviewed opinion, signaling the strength of the court's conviction on the APA issue. The decision was widely viewed as a significant rebuke of Treasury's rulemaking process and raised broader questions about the vulnerability of transfer pricing regulations to APA-based challenges.
D. Ninth Circuit Reversal
The Ninth Circuit reversed the Tax Court's decision, holding that Treasury Regulation Section 1.482-7(d)(2) was a valid regulation entitled to deference under Chevron, U.S.A., Inc. v. Natural Resources Defense Council, Inc., 467 U.S. 837 (1984).
The Ninth Circuit's analysis proceeded in two steps, consistent with the Chevron framework:
Step One — Statutory Ambiguity. The court found that IRC Section 482 is ambiguous as to whether stock-based compensation must be included in the cost pools of qualified cost-sharing arrangements. Section 482 grants the Secretary broad authority to "distribute, apportion, or allocate gross income, deductions, credits, or allowances" among commonly controlled entities to clearly reflect income. The statute does not specifically address CSAs or define the components of shared cost pools, leaving a gap for Treasury to fill through regulation.
Step Two — Reasonable Interpretation. The court found that Treasury's interpretation — that SBC should be included in the cost pool to achieve arm's-length results — was a reasonable construction of the statute. The Ninth Circuit reasoned that SBC represents a real economic cost of compensating the employees who perform the R&D activities that generate the intangible property shared under a CSA. Excluding SBC from the cost pool would systematically understate the true cost of intangible development and shift income to low-tax jurisdictions in a manner inconsistent with the arm's-length standard.
The Ninth Circuit further found that Treasury provided sufficient explanation during the rulemaking process to satisfy the APA's requirements. The court adopted a more deferential standard than the Tax Court in assessing the adequacy of Treasury's response to commenters, holding that Treasury was not required to address every comment point-by-point or to marshal affirmative empirical evidence of arm's-length SBC sharing. Rather, Treasury was required only to articulate a rational basis for its regulatory choice, which the Ninth Circuit found it had done.
A critical element of the Ninth Circuit's reasoning was its conclusion that the arm's-length standard under Section 482 does not require that every element of a CSA cost pool have a directly observable third-party analog in uncontrolled transactions. The court recognized that cost-sharing arrangements between commonly controlled entities are sui generis structures with no perfect uncontrolled comparables, and that Treasury may therefore use its regulatory authority to define what costs must be shared in order to achieve arm's-length results, even in the absence of direct market evidence.
The Supreme Court's denial of certiorari effectively ended the litigation and left the Ninth Circuit's decision as the governing authority within that circuit. The Tax Court's original opinion was vacated, and the regulation remains in force nationwide.
E. Key Holdings and Principles from Altera
The Altera decision, as ultimately resolved by the Ninth Circuit, establishes several principles relevant to transfer pricing enforcement and CSA administration:
1. Validity of CSA Regulations. The Ninth Circuit confirmed the broad authority of Treasury to promulgate transfer pricing regulations under IRC Section 482, including the authority to define the components of cost pools in qualified cost-sharing arrangements under Treasury Regulation Section 1.482-7. This holding reinforces the regulatory foundation upon which PPC's CSA is structured and validates the comprehensive framework set forth in the 2011 final cost-sharing regulations.
2. Chevron Deference to Treasury. Transfer pricing regulations promulgated under Section 482 receive Chevron deference from the courts. This means that challenges to such regulations based on the absence of arm's-length comparables or disagreements with Treasury's economic assumptions face a high burden. A regulation will be upheld so long as it represents a reasonable interpretation of an ambiguous statutory provision, and Treasury is not required to demonstrate that its chosen approach is the only reasonable one.
3. Arm's-Length Standard Flexibility. The arm's-length standard does not require a perfect analog in uncontrolled transactions for every regulatory requirement governing controlled-party transactions. Treasury may adopt reasonable proxies, assumptions, and methodological requirements to operationalize the arm's-length standard, particularly in contexts — such as cost-sharing arrangements — where closely comparable uncontrolled transactions are scarce or nonexistent.
4. APA Rulemaking Standards. Treasury must provide a reasoned basis for its regulatory choices in the notice-and-comment rulemaking process, but the Ninth Circuit set a relatively deferential standard for what constitutes adequate explanation. The court's holding suggests that Treasury need not respond to every comment or marshal affirmative empirical evidence for its position, so long as the final regulation reflects rational decision-making and is not arbitrary or capricious.
F. Applicability to PPC's Positions
1. CSA Cost Pool Composition
PPC's CSA includes qualified R&D costs ranging from $487.3 million to $598.4 million annually during the 2017–2020 period. Altera affirms that the composition of the cost pool under Treasury Regulation Section 1.482-7 is subject to regulatory definition and that Treasury has broad authority to prescribe which categories of costs must be included in a shared development pool.
PPC should confirm that its treatment of stock-based compensation in the CSA cost pool is consistent with the final Altera holding. Specifically, if SBC costs attributable to employees performing qualified R&D activities were excluded from the shared cost pool in PPC's CSA for the years at issue, PPC may have exposure on this point under the regulation upheld by the Ninth Circuit. This is a threshold compliance question that should be verified with Crestfield's contemporaneous documentation. Based on our preliminary review, PPC's CSA documentation indicates that SBC was included in the cost pool for the years at issue, consistent with the regulation, but this should be confirmed.
It is significant, however, that the IRS's current examination does not appear to focus on SBC inclusion as a discrete challenge. Rather, the IRS's proposed adjustments to the CSA relate to the cost-sharing ratios — that is, the allocation percentages applied to the total cost pool — rather than the composition of the cost pool itself. The IRS's position is that PBI's reasonably anticipated benefits are higher than PPC has calculated, warranting higher allocation percentages, not that specific cost categories were improperly excluded from the pool. To that extent, Altera's holding on SBC inclusion is not directly responsive to the IRS's challenge.
2. Regulatory Deference and PPC's Risk
Altera underscores that courts will defer to Treasury's interpretation of Section 482 cost-sharing rules, provided that interpretation is reasonable. This deference cuts both ways for PPC.
On one hand, it supports the regulatory framework PPC relied upon in structuring its CSA. PPC's cost-sharing arrangement was designed in accordance with Treasury Regulation Section 1.482-7, and its cost-sharing methodology — including the calculation of reasonably anticipated benefits and the derivation of cost-sharing percentages — is grounded in the regulatory framework. To the extent the IRS seeks to apply a methodology that departs from the regulatory framework, Altera's affirmation of that framework is helpful to PPC.
On the other hand, Altera's broad deference to Treasury also means that the IRS's interpretation of the regulatory requirements — including the calculation of "reasonably anticipated benefits" under Treasury Regulation Section 1.482-7(e) — will itself receive deference if it is reasonable. PPC cannot assume that its own interpretation of the RAB methodology is the only reasonable one, and it must be prepared to defend the specific inputs and assumptions underlying its calculation against an IRS interpretation that may differ.
PPC's defense on this point should emphasize that its cost-sharing percentages (38.2% to 42.7%) are themselves derived from the regulatory framework, are supported by Crestfield's contemporaneous documentation, and reflect a methodology that is consistent with the regulations as upheld in Altera. The IRS's proposed percentages (48.2% to 53.7%) represent a substantial departure from PPC's calculations and should be subjected to rigorous scrutiny under the same regulatory framework.
3. Limitations of Altera for PPC's Defense
Several limitations constrain the applicability of Altera to PPC's defense:
First, Altera is a Ninth Circuit decision. PPC is headquartered in Princeton Junction, New Jersey, and would litigate in either the U.S. Tax Court (which sits nationwide and applies its own precedents, subject to the Golsen rule requiring it to follow the appellate circuit to which an appeal would lie) or, on appeal, in the United States Court of Appeals for the Third Circuit. The Ninth Circuit's holding is persuasive authority in the Third Circuit but is not binding. The Tax Court's original opinion invalidating the regulation was vacated by the Ninth Circuit's reversal, and the Tax Court has not independently adopted the Ninth Circuit's reasoning in subsequent cases. Accordingly, the precedential weight of Altera outside the Ninth Circuit is persuasive but not controlling.
Second, the core issue in Altera — whether SBC must be included in a CSA cost pool — is factually distinct from PPC's primary exposure areas, which involve cost-sharing ratios and the legacy IP royalty rate. While Altera provides useful general principles regarding Treasury's regulatory authority and the application of the arm's-length standard in the CSA context, it does not directly address the methodological questions at the heart of PPC's examination.
Third, Altera's emphasis on Chevron deference to Treasury could be deployed by the IRS to support its own proposed adjustments if the IRS frames its position as consistent with a reasonable interpretation of the regulations. PPC must be prepared to argue not only that its own methodology is reasonable but also that the IRS's specific methodology is unreasonable or unsupported by the regulatory framework — a higher burden than simply demonstrating that PPC's methodology is permissible.
IV. Harborview Corporation, Inc. v. Commissioner
A. Procedural History
Harborview Corporation, Inc. v. Commissioner has an even more extended procedural history than Altera, spanning three separate decisions over a six-year period. The case was first decided by the United States Tax Court in Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2016-112 (June 9, 2016). The Commissioner appealed the Tax Court's decision to the United States Court of Appeals for the Eighth Circuit, which affirmed in part and remanded in part in Harborview Corporation, Inc. v. Commissioner, 900 F.3d 610 (8th Cir. 2018). On remand, the Tax Court issued a revised decision in Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2022-84 (August 18, 2022) — a decision issued less than one month before the date of this memorandum and therefore representing the most current judicial guidance on the relevant methodological questions.
The case involved a multi-billion-dollar transfer pricing dispute between Harborview Corporation, Inc. (the U.S. parent), one of the world's largest medical device companies, and its wholly-owned manufacturing subsidiary organized in Puerto Rico ("MPROC"). The dispute centered on the arm's-length royalty rate for licenses of intangible property related to implantable cardiac rhythm devices (pacemakers, defibrillators, and related technology) from Harborview Corporation's U.S. operations to MPROC, which manufactured the devices in Puerto Rico for distribution worldwide.
B. Factual Background
Harborview Corporation licensed valuable intangible property — including patents, trade secrets, manufacturing know-how, product designs, and regulatory approvals — to its Puerto Rico subsidiary under an intercompany license agreement. The royalty rate was set based on the comparable uncontrolled transaction ("CUT") method, which is one of the specified methods for evaluating intercompany transfers of intangible property under Treasury Regulation Section 1.482-4(c).
Harborview Corporation's primary CUT was a 1992 license agreement between Harborview Corporation and Halcyon Partners LLC ("Pacesetter"), a third-party company operating in the same industry. Under the Pacesetter license, Harborview Corporation had granted Pacesetter rights to certain cardiac rhythm device technology in exchange for a royalty based on a percentage of net sales. Harborview Corporation argued that the Pacesetter license, with appropriate comparability adjustments, provided a reliable arm's-length benchmark for the intercompany royalty rate charged to MPROC.
The IRS challenged the royalty rate and proposed dramatically higher rates using an alternative methodology — specifically, the comparable profits method ("CPM"), also sometimes referred to as the transactional net margin method ("TNMM") in the OECD framework. The IRS asserted that the Pacesetter license was not a reliable CUT because it involved different intangible property, different contractual terms, and materially different economic conditions than the tested intercompany transaction. The IRS also argued that even if the CUT method were appropriate in theory, the adjustments required to make the Pacesetter license comparable to the MPROC license were so extensive and speculative as to render the CUT method unreliable.
The magnitude of the dispute was enormous. The IRS's proposed adjustments across the examined tax years exceeded $1.4 billion, making Harborview Corporation one of the largest transfer pricing cases in U.S. history by dollar amount. The case attracted substantial attention from the transfer pricing practitioner community, multinational corporations, and tax policymakers, and its outcome has significant implications for the application of transfer pricing methods to intangible property licensing arrangements.
C. Tax Court's Initial Decision (2016)
In its initial decision, the Tax Court sided largely with Harborview Corporation, applying the CUT method and relying on the Pacesetter license agreement as the most reliable comparable uncontrolled transaction.
The Tax Court's analysis proceeded in several steps. First, the court applied the "best method rule" under Treasury Regulation Section 1.482-1(c), which requires the selection of the transfer pricing method that "provides the most reliable measure of an arm's length result" based on all the facts and circumstances. The best method rule considers the degree of comparability between the tested transaction and uncontrolled comparables, the quality and completeness of the underlying data, the reliability of the assumptions required, and the sensitivity of the results to deficiencies in any of these factors.
After extensive analysis of the competing methodologies, the Tax Court found that the CUT method, applied using the Pacesetter license as the comparable transaction, was the best method for determining the arm's-length royalty. The court acknowledged that the Pacesetter license was not a perfect comparable — it involved somewhat different technology, covered a narrower range of products, and was executed under different market conditions — but found that these differences were susceptible to reasonably reliable adjustments.
The Tax Court made detailed adjustments to the Pacesetter-derived royalty rate to account for differences in the intangible property licensed, the functions performed by the parties, the risks assumed, and the economic conditions prevailing at the time of each respective agreement. After applying these comparability adjustments, the Tax Court arrived at a royalty rate that was significantly below the IRS's proposed rate but somewhat above the rate Harborview Corporation had originally applied.
The Tax Court also rejected the IRS's CPM-based alternative analysis. The court found that the IRS's CPM approach was less reliable than the adjusted CUT for several reasons: the comparable companies used by the IRS in its CPM benchmarking study were not sufficiently comparable to MPROC in terms of functions, assets, and risks; the IRS's CPM analysis failed to adequately account for the unique value of Harborview Corporation's intangible property; and the existence of a directly comparable uncontrolled transaction (the Pacesetter license) made reliance on indirect profit-based methods unnecessary and less reliable.
D. Eighth Circuit Decision (2018)
The Eighth Circuit affirmed the Tax Court's selection of the CUT method over the IRS's CPM approach, providing important appellate validation of the Tax Court's methodological determination. However, the Eighth Circuit remanded the case to the Tax Court for reconsideration of certain aspects of the comparability adjustments applied to the Pacesetter royalty rate, finding that the Tax Court had not adequately explained the basis for its specific adjustments.
The Eighth Circuit's key holdings can be summarized as follows:
First, the CUT method can be the best method under Treasury Regulation Section 1.482-1(c) even where the comparable transaction is not perfectly comparable to the tested transaction, provided that the differences between the comparable and the tested transaction can be identified and addressed through appropriate adjustments. The court emphasized that perfect comparability is an unattainable standard and that the best method rule requires selection of the most reliable method, not a perfect one.
Second, the best method rule requires consideration of the reliability of the method selected, the quality of the data underlying the analysis, and the reasonableness of the assumptions employed. These factors must be weighed against the alternatives — a method is not disqualified merely because it requires adjustments, but only if those adjustments are so numerous, substantial, or speculative as to render the method less reliable than an alternative.
Third, and critically for PPC's defense, the Eighth Circuit held that the IRS bears a significant burden of proof when challenging a taxpayer's chosen transfer pricing method, particularly when the taxpayer has contemporaneous documentation supporting that method. The court recognized that taxpayers who prepare and maintain contemporaneous transfer pricing documentation under Treasury Regulation Section 1.6662-6(d) are entitled to a presumption that their chosen methodology was reasonable, and the IRS must demonstrate that its proposed alternative produces a more reliable arm's-length result.
The Eighth Circuit's remand was narrowly focused: it did not question the Tax Court's selection of the CUT method or its rejection of the IRS's CPM approach, but rather required the Tax Court to provide a more detailed explanation of the specific numerical adjustments applied to the Pacesetter royalty rate. The Eighth Circuit found that some of the Tax Court's adjustments lacked adequate explanation in the record and directed the Tax Court to make clearer factual findings regarding the basis for its comparability corrections.
E. Tax Court on Remand (2022)
On remand, the Tax Court issued Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2022-84, on August 18, 2022. This decision, issued less than one month before the date of this memorandum, represents the most current judicial guidance on the application of the CUT method to intangible property royalties and is therefore of immediate relevance to PPC's examination defense.
On remand, the Tax Court reaffirmed its selection of the CUT method as the best method for determining the arm's-length royalty rate for the MPROC license. The court conducted a more detailed and thorough analysis of functional comparability, intangible property characteristics, and economic conditions affecting the Pacesetter license as compared to the tested transaction. The Tax Court applied revised comparability adjustments that were more fully explained and documented than those in its original decision, resulting in a modified royalty rate that differed somewhat from the rate determined in the original 2016 opinion.
The Tax Court again rejected the IRS's CPM-based approach, finding it less reliable than the adjusted CUT. The court noted that the IRS's profit-based analysis suffered from the same deficiencies identified in the original decision — including insufficient comparability of the benchmark companies and failure to adequately account for the unique value of Harborview Corporation's intangible property — and that these deficiencies had not been cured on remand.
The Tax Court's remand decision is significant for several reasons relevant to PPC. First, it demonstrates the Tax Court's sustained commitment to the CUT method as the best method when a comparable uncontrolled transaction is available, even when that transaction requires substantial adjustments. Second, it provides a detailed template for the type of comparability analysis that will satisfy the Eighth Circuit's requirements for adequate explanation — a template that PPC and WVG should follow in structuring their own CUT analysis. Third, it reaffirms the Tax Court's skepticism toward the IRS's reliance on profit-based methods as substitutes for CUTs in intangible property licensing disputes.
F. Key Holdings and Principles from Harborview Corporation
The Harborview Corporation litigation, taken as a whole across its three decisions, establishes several principles of direct relevance to PPC's examination defense:
1. Best Method Rule (Treas. Reg. § 1.482-1(c)). The CUT method can be the best method for determining arm's-length royalty rates for intangible property, even when the comparable transaction requires significant adjustments, if those adjustments are reasonably quantifiable and the underlying transaction is sufficiently comparable in economic substance. The selection of the best method is a facts-and-circumstances determination, and the CUT method is not disqualified merely because the comparable transaction is imperfect.
2. Comparability Standard for CUTs. Perfect comparability between the tested transaction and the uncontrolled comparable is not required. The relevant inquiry is whether the material differences between the two transactions can be reliably identified and adjusted for, taking into account the following factors:
(a) The nature and economic significance of the intangible property transferred or licensed in each transaction;
(b) The contractual terms of each transaction, including duration, exclusivity, geographic scope, and sublicensing rights;
(c) The economic conditions and market environment prevailing at the time of each transaction; and
(d) The functions performed, assets employed, and risks assumed by each party to the respective transactions.
3. Burden on the IRS. When a taxpayer relies on the CUT method and has contemporaneous transfer pricing documentation supporting its methodology, the IRS bears a heavy burden to demonstrate that its alternative methodology produces a more reliable arm's-length result. The IRS cannot simply assert that the taxpayer's CUT is imperfect; it must affirmatively demonstrate that its own methodology is more reliable under the best method rule.
4. Rejection of IRS's Reliance on CPM Where CUTs Exist. Both the Tax Court and the Eighth Circuit found that the IRS's CPM/profit-split analysis was less reliable when a directly comparable uncontrolled transaction existed, even an imperfect one. Profit-based methods are generally considered less reliable than transactional methods for intangible property transfers because they do not directly measure the arm's-length price or royalty for the specific intangible at issue.
5. Importance of Expert Economic Analysis. Both the Tax Court and the Eighth Circuit relied heavily on expert testimony regarding comparability adjustments, discount rates, revenue projections, and other elements of the economic analysis. The quality, rigor, and credibility of expert witnesses — particularly transfer pricing economists — were significant factors in the court's assessment of each party's methodology.
G. Applicability to PPC's Positions
1. Defense of the 4.5% Legacy IP Royalty Rate
Harborview Corporation provides the strongest precedential support for PPC's defense of the 4.5% royalty rate on legacy pharmaceutical compounds licensed from PPC to PBI.
WVG's CUT analysis, led by Dr. Helena Vasquez (Managing Director) as lead economist, identified 14 comparable uncontrolled pharmaceutical license agreements involving the license of mature or late-lifecycle pharmaceutical compounds in therapeutic categories broadly comparable to PPC's legacy product portfolio. The 14 CUTs were selected through a systematic search process using recognized databases (including Calderon Data Systems's Pharmaprojects database, the RoyaltySource pharmaceutical licensing database, and SEC filings) and were screened for comparability using criteria consistent with Treasury Regulation Section 1.482-4(c)(2).
The 14 CUTs yielded an interquartile range ("IQR") of 3.1% to 6.8% and a median of 4.4%. PPC's 4.5% royalty rate falls squarely within this interquartile range and is virtually at the median — within ten basis points — of the comparable data set. Under the arm's-length range provisions of Treasury Regulation Section 1.482-1(e)(2), a tested result that falls within the interquartile range of comparable results is generally regarded as within the range of arm's-length results, and no adjustment is warranted.
The IRS proposes an 11.0% rate based on its own selected CUTs. Under the Harborview Corporation framework, the IRS must demonstrate that its CUT selections are more reliable than PPC's — that is, that the IRS's comparable transactions are more closely comparable to PPC's legacy compound license than the 14 transactions identified by WVG. PPC should challenge the IRS's CUT selection criteria on multiple comparability grounds, including the nature of the intellectual property (early-stage vs. late-lifecycle), the therapeutic area (specialty vs. primary care), the geographic scope of the license (global vs. regional), and the exclusivity and sublicensing terms.
Harborview Corporation teaches that the comparability analysis must be rigorous and granular: courts will examine each claimed comparable in detail and assess whether the material differences between the comparable and the tested transaction have been identified and reliably adjusted for. PPC should be prepared to demonstrate, on a transaction-by-transaction basis, that the 14 CUTs identified by WVG are more closely comparable to PPC's legacy compound licenses than the transactions relied upon by the IRS.
2. Best Method Rule Application
Harborview Corporation reinforces that under the best method rule of Treasury Regulation Section 1.482-1(c) and (d), the CUT method is generally the most reliable method for evaluating intangible property licensing arrangements when comparable uncontrolled transactions are available. PPC can argue that the CUT method is the best method for evaluating the 4.5% royalty rate for several reasons that, taken together, make PPC's CUT analysis even more robust than the analysis upheld in Harborview Corporation:
• Multiple CUTs are available. PPC's CUT analysis relies on 14 comparable license agreements, as compared to the single Pacesetter license relied upon in Harborview Corporation. The availability of multiple CUTs provides a broader and more statistically reliable data set, reduces the risk of outlier bias inherent in reliance on a single comparable, and enhances the overall reliability of the arm's-length range determination.
• The interquartile range strongly corroborates PPC's rate. The IQR of 3.1% to 6.8% is a relatively narrow band, suggesting that the comparable transactions reflect a consistent market practice for royalties on late-lifecycle pharmaceutical compounds. PPC's 4.5% rate falls within this range and is supported by the central tendency (median of 4.4%) of the data set.
• PPC's rate was established contemporaneously. The 4.5% royalty rate was established as of July 1, 2012, based on then-available market data and a benchmarking study conducted by Crestfield. The contemporaneous nature of the rate determination is significant under Harborview Corporation, which emphasizes that the IRS bears a heavier burden when challenging a rate that was established based on a reasoned, contemporaneous analysis rather than reverse-engineered after the fact.
3. IRS's CUT Methodology Challenge
If the IRS relies on CUTs showing royalty rates closer to 11.0%, PPC should scrutinize the comparability of those transactions using the analytical framework articulated in Harborview Corporation. Specifically, PPC should examine the following factors for each of the IRS's claimed comparables:
• Therapeutic category. Did the IRS's CUTs involve the same or similar therapeutic categories as PPC's legacy compounds (primarily oncology, immunology, and rare disease)? Royalty rates in the pharmaceutical industry vary significantly by therapeutic area, and CUTs from unrelated therapeutic categories may not be reliable comparables.
• Product lifecycle stage. Were the licensed compounds in the IRS's CUTs at a similar stage in their product lifecycle as PPC's legacy compounds? PPC's legacy products are mature, declining-revenue compounds approaching or past patent expiration. CUTs involving early-stage, high-growth compounds would be expected to command higher royalty rates and would not be comparable to PPC's licenses.
• Geographic territories. Were the geographic territories in the IRS's CUTs comparable to the territories covered by PPC's legacy IP license (non-Americas)? Licenses covering global territories or large single-market territories (such as the United States) may reflect different risk profiles and revenue potential than non-Americas regional licenses.
• Contractual terms. Were the contractual terms of the IRS's CUTs comparable to PPC's license? Key terms to examine include duration, exclusivity, sublicensing rights, termination provisions, and milestone or minimum royalty obligations. Differences in these terms can materially affect the appropriate royalty rate.
Harborview Corporation requires that material differences between the tested transaction and the comparable be addressed through reliable adjustments, not dismissed. If the IRS's CUTs involve materially different intangible property, geographic scope, or contractual terms, the IRS must demonstrate that it has made appropriate adjustments to account for those differences — and that those adjustments are more reliable than the comparability adjustments applied by WVG to its 14 CUTs.
4. CPM/TNMM as an Alternative
In addition to the CUT analysis, WVG conducted a corroborative analysis under the comparable profits method / transactional net margin method ("CPM/TNMM"), testing PBI's operating margins against 22 comparable distributors and IP-holding companies in the pharmaceutical sector. WVG's CPM/TNMM analysis confirmed that PBI's operating margins fall within the interquartile range of the comparables in all four years at issue (2017–2020), providing additional support for the arm's-length nature of the intercompany pricing.
Under Harborview Corporation, where CUTs are available, the CUT method should take precedence over profit-based methods such as CPM and TNMM. However, the availability of a corroborative CPM/TNMM analysis strengthens PPC's overall position by demonstrating that the arm's-length character of the intercompany arrangements is confirmed under multiple independent methodologies. This "belt and suspenders" approach is consistent with the best method rule's emphasis on considering all available evidence of an arm's-length result.
5. PCT Valuation and Income Method
While Harborview Corporation primarily addressed royalty rates for ongoing intangible property licenses rather than lump-sum PCT valuations, the principles articulated in the decision regarding discount rate selection and revenue projection methodology are directly relevant to PPC's PCT valuation defense.
WVG used a WACC of 9.8% for the PCT income-method / DCF analysis, yielding a valuation range of $278 million to $361 million. The IRS used a WACC of 7.2%, yielding a valuation of $852 million. The 260 basis point difference in discount rates accounts for the vast majority of the $491 million to $574 million disparity between the two valuations.
Harborview Corporation underscores that assumptions regarding discount rates, revenue projections, growth rates, and other inputs to DCF analyses must be supportable and internally consistent, and that courts will critically examine the reasonableness of both parties' inputs. PPC should be prepared to demonstrate that WVG's 9.8% WACC reflects the risk profile of pre-revenue and early-lifecycle pharmaceutical intangibles in PBI's markets, incorporating industry-specific risk premiums for regulatory approval risk, market access and pricing risk, foreign exchange risk, and country-specific risk factors in PBI's non-Americas territories.
Conversely, PPC should challenge the IRS's 7.2% WACC as unreasonably low for pharmaceutical intangibles at the stage of development reflected in the CSA. A 7.2% WACC is more consistent with the cost of capital for a diversified, large-cap pharmaceutical company than with the risk-adjusted return required for pre-revenue intangible assets in development. The IRS's failure to adequately risk-adjust the discount rate is the type of analytical deficiency that Harborview Corporation identifies as undermining the reliability of an economic analysis.
6. Role of Contemporaneous Documentation
Harborview Corporation reinforces the significance of contemporaneous transfer pricing documentation in establishing the reasonableness of a taxpayer's chosen methodology and the reliability of the underlying economic analysis. Both the Tax Court and the Eighth Circuit gave weight to the fact that Harborview Corporation had established its royalty rate based on a reasoned analysis conducted at the time of the transaction, rather than developing its position retroactively in response to the IRS examination.
PPC's contemporaneous transfer pricing documentation was prepared by Crestfield & Associates LLP under the supervision of Susan Lam, Transfer Pricing Partner, in accordance with the penalty-protection standards of IRC Section 6662(e)(3)(B) and Treasury Regulation Section 1.6662-6(d) for all four years at issue (2017–2020). This documentation establishes the CSA and royalty methodologies under Treasury Regulation Sections 1.482-4 and 1.482-7 and provides a detailed economic analysis supporting the cost-sharing ratios, the 4.5% royalty rate, and the PCT valuation.
The existence of this contemporaneous documentation creates a strong factual foundation for PPC's defense under Harborview Corporation. It demonstrates that PPC's transfer pricing positions were not developed in hindsight but were established based on a rigorous, contemporaneous analysis conducted by qualified professionals. It also supports PPC's reasonable-cause defense against the proposed Section 6662(e) penalty, as discussed further in Section VI.D below.
V. Comparative Analysis: Altera and Harborview Corporation Together
A. Common Themes
Despite their different factual contexts and procedural postures, Altera and Harborview Corporation share several common themes that bear on PPC's examination defense.
Both cases underscore the primacy of the arm's-length standard under IRC Section 482 and the regulatory framework promulgated thereunder. In both cases, the courts evaluated the disputed transfer pricing issues through the lens of the arm's-length standard, assessing whether the intercompany arrangements at issue reflected the pricing that would have been agreed upon by unrelated parties transacting at arm's length. This analytical framework is the cornerstone of PPC's defense and should be the organizing principle for all of PPC's submissions to the IRS examination team.
Both cases establish that the IRS bears a significant evidentiary burden when challenging a taxpayer's contemporaneously documented transfer pricing methodology. In Altera, the IRS prevailed because the regulation it sought to enforce had been promulgated through the formal rulemaking process and was entitled to Chevron deference; but even there, the court evaluated whether Treasury had provided an adequate explanation for its regulatory choice. In Harborview Corporation, the IRS failed to meet its burden of demonstrating that its CPM-based alternative methodology was more reliable than the taxpayer's CUT-based approach, particularly where the taxpayer had contemporaneous documentation supporting its chosen method. Together, these cases establish that the IRS cannot simply disagree with a taxpayer's methodology; it must affirmatively demonstrate that its proposed alternative is superior under the best method rule.
Both cases emphasize the importance of rigorous economic analysis and expert testimony. In Altera, the Tax Court's initial decision turned in part on the quality of the economic evidence in the rulemaking record regarding whether arm's-length parties would share SBC costs. In Harborview Corporation, the Tax Court and the Eighth Circuit both relied heavily on expert testimony from transfer pricing economists regarding comparability adjustments, discount rates, and the reliability of the competing methodologies. PPC should ensure that WVG's economic analyses are structured to withstand the level of judicial scrutiny applied in both decisions.
B. Distinguishing Features Relevant to PPC
The following table summarizes the key distinguishing features of Altera and Harborview Corporation and their respective applicability to PPC's positions:
As this comparison illustrates, Harborview Corporation is the more directly applicable precedent for PPC's two largest exposure areas — the legacy IP royalty rate and the PCT valuation — while Altera is more relevant to the CSA cost-pool composition and structural questions. The combination of the two cases provides a comprehensive analytical framework for PPC's defense strategy.
C. Jurisdictional Considerations
PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. If PPC were to petition the United States Tax Court following the issuance of a statutory notice of deficiency, the Tax Court's own precedents would govern the resolution of the case, subject to the Golsen rule. Under Golsen v. Commissioner, 54 T.C. 742 (1970), the Tax Court follows the law of the circuit to which an appeal would lie when that circuit has addressed the issue. An appeal from a Tax Court decision involving PPC would lie in the Third Circuit, based on PPC's principal place of business.
The Tax Court's Harborview Corporation decisions — both the original 2016 opinion and the 2022 remand opinion — are directly applicable as Tax Court precedent. Because the Tax Court itself decided Harborview Corporation, its holdings regarding the best method rule, the comparability standard for CUTs, and the burden on the IRS are binding on the Tax Court in subsequent cases, absent a contrary holding by the Third Circuit.
Altera's Ninth Circuit holding is persuasive but not binding in the Third Circuit. However, it represents the current state of the law on the requirement that SBC be included in CSA cost pools, given that the Tax Court's original opinion invalidating the regulation was vacated by the Ninth Circuit's reversal. The regulation upheld in Altera — Treasury Regulation Section 1.482-7(d)(2) — applies nationwide by its terms, and there is no circuit split on its validity at present. Accordingly, while the Third Circuit would not be bound by the Ninth Circuit's reasoning, the practical effect is that the SBC regulation is in force and enforceable until a court in another circuit reaches a contrary conclusion.
Neither the Third Circuit nor the Tax Court has addressed transfer pricing methodology questions on facts closely analogous to PPC's — specifically, the application of the CUT method to pharmaceutical intangible property royalties or the valuation of a PCT in a pharmaceutical CSA. This absence of directly controlling authority means that both Altera and Harborview Corporation serve as important persuasive authorities, and PPC should cite them prominently in any judicial proceeding while acknowledging the jurisdictional limitations.
Additionally, PPC should be aware that if the case were litigated in the Tax Court, the Eighth Circuit's 2018 opinion in Harborview Corporation — while not binding under Golsen in a Third Circuit appeal — would be given significant weight as the only appellate court to have addressed the application of the best method rule to intangible property royalty disputes in this depth. The Third Circuit, if called upon to address these issues for the first time, would likely look to the Eighth Circuit's analysis as persuasive guidance.
VI. Strategic Recommendations
Based on the analysis set forth above, we make the following strategic recommendations for incorporating the Altera and Harborview Corporation precedents into PPC's examination defense at each stage of the proceedings.
A. For the IDR Response Phase (Current)
PPC is currently in the Information Document Request ("IDR") response phase of the examination. The IRS examination team has issued multiple IDRs requesting transfer pricing documentation, economic analyses, and supporting data. We recommend the following actions during this phase:
Cite Harborview Corporation in narrative responses regarding the royalty rate methodology. Any narrative responses to IDRs regarding the basis for PPC's 4.5% legacy IP royalty rate should cite Harborview Corporation to establish that the CUT method, supported by 14 comparable pharmaceutical license agreements with an interquartile range of 3.1% to 6.8% and a median of 4.4%, is the best method under Treasury Regulation Section 1.482-1(c) and (d). PPC's narrative should emphasize that the CUT analysis is even more robust than the analysis upheld in Harborview Corporation, which relied on a single comparable transaction, and that PPC's rate falls squarely within the arm's-length range.
Confirm compliance with Altera regarding SBC treatment. In responding to IDRs regarding the CSA cost pool composition, PPC should confirm that its treatment of stock-based compensation is consistent with the Altera holding and Treasury Regulation Section 1.482-7(d)(2). To the extent the IRS examination team has not yet raised SBC as a specific issue, PPC should avoid volunteering information on this topic beyond what is required by the IDR, but should ensure that its CSA documentation reflects SBC inclusion in the cost pool in conformity with the regulation.
Coordinate with WVG on comparability analysis. PPC should coordinate with WVG — specifically, Dr. Helena Vasquez and Dr. Rohan Chakrabarti — to ensure that the economic analyses being prepared and produced in response to IDRs are structured to withstand the type of granular comparability scrutiny applied by the Tax Court in the Harborview Corporation remand decision. Each of the 14 CUTs should be accompanied by a detailed comparability analysis addressing the nature of the licensed intangible property, the contractual terms, the economic conditions, and the functions, assets, and risks of the parties.
B. For a Potential Protest and Appeals
If the IRS issues a Revenue Agent Report proposing

MEMORANDUM

EXAM TEAM ID: LB&I-NE-TP-2022-00641

Record

Parties

Dates

Amounts